Terapio is a biopharmaceutical company developing therapeutics based on the RLIP76 protein.
Terapio is developing a pipeline of therapies based on the normally-occurring transport protein RLIP76 that moves free-radical toxins out of cells before significant damage can occur. Although naturally present in cells, increasing the amount of this protein available to normal cells affords them an even greater ability to deal with toxins from a variety of sources, including chemicals and radiation.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 18, 2008 | Series Unknown | $1.70M | 1 | Texas Wide Open for Business | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Texas Wide Open for Business | Yes | Series Unknown |